{"schema_version":"secwatch.filing_event.v1","accession":"0002007919-26-000020","form_type":"8-K","ticker":"INBX","cik":"0002007919","company_name":"Inhibrx Biosciences, Inc.","filed_at":"2026-05-11T20:02:50+00:00","discovered_at":"2026-05-11T20:04:03.457037+00:00","generated_at":"2026-05-11T22:57:08.127474+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Inhibrx: INBRX-106 + pembro achieves 44% ORR vs 21.4% in HNSCC Phase 2","bullets":["Confirmed ORR 44.0% (11/25) for combo vs 21.4% (6/28) for pembro alone; absolute increase 22.6%.","Three complete responses in combo arm vs zero in control; deeper tumor reductions overall.","Up to 15-fold increase in CD8+ and CD4+ T-cell proliferation in combo arm (vs up to 2.5-fold).","No treatment-related deaths; most common AEs: rash, diarrhea, fatigue, infusion reactions.","Phase 3 HexAgon start Q3 2026; perioperative NSCLC study later this quarter; metastatic NSCLC in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0002007919-26-000020","json":"https://secwatch.observer/filing/0002007919-26-000020.json","markdown":"https://secwatch.observer/filing/0002007919-26-000020.md","text":"https://secwatch.observer/filing/0002007919-26-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000020/0002007919-26-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007919/000200791926000020/inhibrx-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:57:08.127474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}